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Despite interventions being available, it is estimated that pneumonia is responsible for 15% of childhood deaths worldwide1. Reductions in annual mortality remain modest, with nearly 950,000 under-5 year 
olds dying of pneumonia in 2013 (ref. 2). Despite the unprecedented rate of 
Haemophilus influenzae type B (Hib) and pneumococcal vaccine (PCV) in-
troduction, achieving high levels of coverage in developing countries is still 
challenging3. Therefore, in regions where vaccine introduction and scale-up 
lags behind other countries, improved access to diagnosis and treatment is 
crucial. This includes interventions at multiple points in the continuum of care 
— improving care-seeking practices, increasing the availability of suitable di-
agnostics, and guiding both formal and informal care providers in appropriate 
disease management. Unfortunately, current treatment coverage remains low, 
and, more importantly, most childhood pneumonia deaths result from a lack 
of, or delay in, accurate diagnosis4. 
A crucial component of improving pneumonia outcomes is the early iden-
tification of patients at risk of treatment failure and the timely provision of 
supportive care. However, in the absence of appropriate prognostic tools at 
the frontline, currently recommended World Health Organization (WHO) 
guidelines for integrated management of childhood illness (IMCI) often lead 
to an overuse of antibiotics and the under-referral of patients with severe 
pneumonia who require hospital care5. The most recent 2015 technical up-
date of IMCI guidelines defines non-severe pneumonia as the presence of fast 
breathing or chest in-drawing or both, which is treatable with oral antibiotics. 
Severe pneumonia is defined as cough or difficulty breathing in the presence of 
danger signs, and requires referral to a hospital or health facility for injectable 
antibiotics or other supportive care such as oxygen therapy6. Currently, iden-
tification of these IMCI symptoms remains inconsistent and unreliable among 
community health-care workers or carers without clinical training7. Therefore, 
improved prognostic and diagnostic tools for case-management are neces-
sary to substantially reduce pneumonia-associated morbidity and mortality. 
Hypoxaemia and malnutrition are strong predictors of mortality in children 
who are hospitalized for pneumonia8,9. This has led to increasing support for 
the use of oxygen therapy and monitoring oxygen saturation in the manage-
ment of severe cases. It is estimated that 15% of children who are hospitalized 
for pneumonia have hypoxaemia (oxygen saturation, or SpO2, of <90% (ref. 
10) and that around 1.5 million children with severe pneumonia require oxygen 
treatment each year11. The use of pulse-oximetry devices (used to measure the 
oxygen level in the blood) in community health-care settings has been proposed 
as a method to identify hypoxic children at risk of treatment failure. These de-
vices may be particularly beneficial at the frontline given that they require little 
training and reduce the reliance on clinical symptoms. The current pulse-oxi-
metry systems are also quick, non-invasive and require minimal infrastructure. 
The aim of this study was to evaluate the public health impact and 
cost-effectiveness of current IMCI guidelines combined with pulse-oximetry 
devices as a prognostic tool in the hands of frontline health workers in re-
source-poor settings. To do this, we developed a model of disease progression 
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that explicitly tracks the continuum of care pathways, and parameterized the 
model for the top 15 countries with the highest burden of pneumonia.
METHODS
Model structure. The progression and treatment of pneumonia in a population of 
children under the age of five was modelled using a continuous-time determin-
istic compartmental model (Fig. 1). Full mathematical details of the model are 
given in the Supplementary Information. Without treatment, children may be in 
one of four states: susceptible (S), non-severe (NSV), severe (SV) or death (D). 
These definitions of non-severe and severe disease are different to those defined 
by IMCI. We classified severe disease as disease that requires hospitalization 
and non-severe disease as disease that can be successfully managed with oral 
antibiotics alone. Susceptible children become infected at a constant rate deter-
mined by the incidence of pneumonia in the population, and although most enter 
the non-severe state before progressing, a small proportion progress directly to 
severe disease. Children with non-severe disease may recover naturally (without 
treatment), progress to a treatment state or progress to the severe state. Chil-
dren with severe disease may recover naturally, progress to a treatment state, or 
die and be tracked in the death state. Each of the non-severe disease and severe 
disease states are further subdivided into day of infection. Children with non-se-
vere pneumonia who have not progressed to severe disease or recovered natu-
rally after 14 days return to the susceptible state, whereas children with severe 
pneumonia who have not received treatment or recovered naturally after 14 days 
(giving a maximum potential illness length of 28 days) are assumed to have died.
As well as making a natural recovery, non-severe and severe cases may 
separately enter one of two treatment states: treatment received outside of 
hospital (referred to as community-based treatment) or hospital-based treat-
ment, at rates that depend on the care-seeking rate and factors in the care 
pathway. The latter is determined by a decision tree in which four factors 
are included: availability of a prognostic tool, whether or not the prognostic 
tool gives the correct result, adherence to the prognosis (whether or not the 
correct treatment, according to the prognosis, was administered by the med-
ical practitioner and followed by the patient) and treatment availability. An 
example of a section of the decision tree is given in Supplementary Figure 1. 
We aimed to capture correct and incorrect treatment rates of both non-severe 
and severe cases, so cases may move into either treatment state depending on 
the outcome of the decision tree, regardless of whether or not it is the correct 
treatment. Moreover, this design includes the possibility that cases can move 
into the correct treatment state even if the prognosis was incorrect.
Last, if treatment fails to work, then the case may move into one of two 
treatment failure states, determined by a probability of treatment success that 
depends on both the severity of the disease and whether the treatment is ap-
propriate. For example, severe cases are less likely to be cured by communi-
ty-based treatment than hospital-based treatment. Children with non-severe 
disease that fail to respond to treatment may progress to hospital treatment, 
to a severe state or naturally recover to the susceptible state. Children with 
severe disease who fail to respond to treatment may progress to hospital 
treatment, to the death state or naturally recover to the susceptible state at 
different rates to the non-severe cases.
Community-based treatment is assumed to consist of a course of amox-
icillin that lasts for 3 days, whereas hospital-based treatment lasts for 7 days. 
To ensure that treatment does not prolong illness in the model, those who 
enter the treatment states at a late stage of infection (such as day 13 or 14 
of non-severe illness) are assumed to recover before reaching the end of the 
treatment, instead of progressing through all 3 or more days of treatment and 
therefore taking longer to return to susceptible than if they are left untreated 
(see Supplementary Fig. 2).
Model parameters. The public health impact of the introduction of pulse-oxi-
metry devices was evaluated at the community level in comparison to a baseline 
standard of care with IMCI by calculating the incremental deaths averted with 
the introduction of pulse oximetry in different countries. Countries included in 
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Figure 1 | Overview of model structure. The main states and transitions of the model are shown, with cases transitioning at time-dependent rates. Each state contains 
a subset of states to track the length of infection. 
FLOYD ET AL. | PULSE OXIMETRY
528 | 7580 | 3 December 2015 S55
the analysis were selected according to the number of pneumonia-attributed 
deaths that occur each year in that country, using estimates from 2011 (ref. 12). 
Although more recent estimates of pneumonia mortality in under-fives are 
available, these did not include estimates of the number of cases and so the 
2011 estimates were used for the analysis. The 15 countries with the highest 
number of deaths were chosen, excluding China, Angola and Tanzania owing 
to a lack of data on the availability of community-based care in these countries. 
The incidence of pneumonia in the model was fitted to the mortality data 
by finding the incidence rate that best matches the mortality data using a nor-
mal likelihood. The rate of progression from non-severe to severe disease was 
fitted to estimates of proportions of cases that progress to severe disease12,13. 
All other disease progression parameters were based on a review of the lit-
erature and expert opinion (Table 1). The availability of community-based 
care was fitted simultaneously to data on the percentage of children with 
Parameter Value (range) Sources
Disease progression
Incidence Country-specific ± 10% Ref. 12
Proportion severe on day 1 5% (2–10%) Ref. 13
Mean duration of non-severe illness before recovery 3 days (2–4 days) Ref. 25
Mean duration of non-severe illness before progression to severe illness 10 days (9–11 days) Estimated from model (see Methods)
Mean duration of severe illness before recovery 4 days (3–5 days) Ref. 22
Mean duration of severe illness before death 7 days (6–8 days) Ref. 26
Proportion bacterial versus viral (NSV) 85% viral (75–90%)
15% bacterial (25–10%)
Ref. 27
Proportion bacterial versus viral (SV) 85% bacterial (75–90%)
15% viral (25–10%)
Assumed
Care-seeking and health-care parameters
Mean duration of illness before care seeking NSV 3 (2–4) days
SV 0.75 (0.5–1) days
Ref. 26
Probability that community-based treatment is available Country-specific ± 10% Ref. 3
Probability that timely hospital access 0.61 ± 10% Ref. 24
Probability of community-based treatment curing non-severe bacterial case 0.925 (0.90–0.95) Ref. 28
Probability of treatment with hospital care curing case 0.925 (0.80–0.95) Assumed to be high if oxygen is available with lower values representing poorer 
standard of care
Probability of treatment with amoxicillin curing severe case if prescription adhered to 0.65 (0.6–0.7) Ref. 29 (based on treatment failure rates of patients with hypoxia at baseline) 
Prognostic parameters
Probability of prognostic available 1 (0.9–1) Assumed to be high for the purpose of this analysis
Sensitivity of IMCI 0.55 (0.5–0.6) Ref. 30
Sensitivity of PO1 0.7 (0.65–0.75) Estimated
Sensitivity of PO2 0.85 (0.8–0.9) Ref. 14
Specificity of IMCI 0.85 (0.8–0.9) Assumed to be high given low overall referral rates
Specificity of PO1 and PO2 0.85 (0.8–0.9) Assumed to be similar to IMCI
Adherence to non-severe prognosis (IMCI) 0.55 (0.5–0.6) Refs 31–33
Adherence to severe prognosis (IMCI) 0.65 (0.6–0.7) Refs 31,32
Adherence to non-severe prognosis (PO1 and PO2) 0.55 (0.5–0.6) Assumed to be similar to IMCI
Adherence to severe prognosis (PO1 and PO2) 0.85 (0.8–0.9) Assumed to be high for the purpose of this analysis
Prognosed SV treated with community-based treatment versus nothing 1 Assumed that prognosed SV will always be treated even if not referred to hospital
Prognosed NSV that is hospitalized versus receiving nothing 0.025 (0.01–0.05) Assumed that prognosed NSV are unlikely to be incorrectly hospitalized
IMCI, integrated management of childhood illness; NSV, non-severe pneumonia; PO1, IMCI and pulse oximetry combination with a sensitivity of 70%; PO2, IMCI and pulse oximetry combination with a 
sensitivity of 85%; SV, severe pneumonia. 
Parameter Value (range) Sources
Amoxicillin treatment per child US$0.1614 drug cost plus 
country-specific delivery cost 
(± 10%)
Ref. 34
Average hospital cost per episode Country-specific (± 10%) Ref. 15
Pulse oximeter $250 Ref. 35
Batteries $2 ($1.5–2.5) Assumed
Uses per set of batteries 840 Ref. 36
Lifetime of device 2 years Ref. 36
Number of devices needed 1 per 1,000 children under 5 
(0.8–1.2)
Assumed 
Delivery and distribution costs 20% Assumed
Table 1 | Model parameters. The central estimates shown are derived from the source literature with ranges added for the sensitivity analysis.
Table 2 | Cost parameters. The central estimates are shown derived from the source literature with ranges added for the sensitivity analysis.
PULSE OXIMETRY | FLOYD ET AL.
S56 3 December 2015 | 7580 | 528
suspected pneumonia receiving antibiotics3, assuming a binomial likelihood, 
whereas the other care-seeking parameters were obtained from the literature 
where available (Table 1). One care-seeking parameter — the probability of 
treatment with hospital care curing the case — could not be identified in the 
literature. For the purpose of assessing the impact of the pulse oximeter as 
a prognostic tool, we assumed that this was high, representing a situation in 
which oxygen and other facilities are available. Lower values of this parameter 
will reduce the impact and cost-effectiveness of any prognostic tool; this was 
explored in our sensitivity analysis.
To estimate the impact and cost-effectiveness of a new prognostic com-
bination (IMCI and pulse oximetry), we also needed to make a number of 
assumptions about its availability, its ability to accurately classify a case as 
severe (sensitivity) or non-severe (specificity) compared with IMCI alone, and 
adherence to its use. For the purposes of assessing its utility, we assumed it 
would be made available and hence set this parameter to a high value. Al-
though data were available to support the sensitivity of IMCI, sufficient data 
were not available to inform the sensitivity of IMCI when combined with pulse 
oximetry. Thus, we proposed two scenarios: one in which the addition of pulse 
oximetry increases the sensitivity of IMCI to 70% (referred to as PO1), and 
one in which the sensitivity of the combination is increased to 85% (referred 
to as PO2), reflecting the potential of pulse oximetry to identify both people 
with hypoxic cases and cases with abnormal oxygen saturation (90–95%) 
who would benefit from referral14. We could not find data on specificity and 
assumed these would be relatively high (85%) for both IMCI alone and the 
PO1 and PO2 prognostic packages (Table 1). Adherence to IMCI guidelines 
for both non-severe and severe cases was based on the literature, and we set 
severe prognosis adherence to the PO1 and PO2 prognostic packages to be 
higher (increased from 65% to 85%), reflecting the perception that a phys-
ical tool would increase the likelihood of adherence. Finally, two parameters 
are included to account for non-adherence to the prognosis. For those whose 
prognosis is severe disease, if the mother did not take the child to hospital de-
spite referral we assumed that as a minimum the child would receive amoxicil-
lin (taking into account its availability). For those with a non-severe prognosis, 
but for whom the treatment regimen was not adhered to, we assumed that 
they had a high probability of receiving no treatment.
Costing approach. The incremental cost-effectiveness of pulse oximetry was 
evaluated in comparison to a baseline of using IMCI alone. Costing was under-
taken from a public health provider perspective and hence no societal, econom-
ic or private sector costs were included. 
Costs were subdivided into two categories. Additional direct costs included 
the cost of prognostic equipment, batteries and delivery and distribution of the 
prognostic tool. Further health-care costs included additional amoxicillin cours-
es for patients with non-severe disease, increased hospitalization costs for pa-
tients with severe disease and the cost savings that would arise from the reduc-
tion in inappropriate amoxicillin prescriptions or treatment (owing to assumed 
increased prognostic adherence) or hospital referral. Total costs are the direct 
costs plus the additional health-care costs. Wherever possible, costing data 
were obtained from the literature (Table 2). Health-care costs were obtained at 
the country level from the WHO–CHOICE database15. This included the average 
cost of an outpatient visit and the cost of inpatient stays based on an average of 
7 days of hospitalization. The cost implications arising from potential overuse 
of amoxicillin (antibiotic resistance) were not included in the analysis given the 
difficulty of obtaining any meaningful quantitative estimate of this16. Disabili-
ty-adjusted life years (DALYs) are calculated using country-specific life-expec-
tancy values and are not discounted or age-weighted, as suggested by recent 
recommendations17. The overall cost-effectiveness compared with IMCI is then 
presented as the cost per DALY averted compared with IMCI. 
Sensitivity analysis. To explore sensitivity to key parameters, Latin hypercube 
sampling was used to draw 1,000 different parameter values from a triangular 
distribution. Outputs from the model were calculated using each set of pa-
rameters and the top and bottom 5% of the results were discarded to obtain 
90% ranges. Additional sensitivity analyses are reported in the Supplementary 
Information. 
RESULTS
Figure 2a shows previous annual pneumonia mortality estimates12 and our es-
timates of the incidence of pneumonia per 1,000 children in the 15 countries 
with the highest burden. As expected, the estimated pneumonia incidence fol-
lows a similar pattern to mortality, but with variations owing to between-coun-
try variation in the availability of community-based care. Niger, Ethiopia and 
India are estimated to have particularly low rates of antibiotic treatment18, and 
thus are predicted by the model to have the highest case-fatality rates.
The predicted mortality across the 15 countries under different types of 
prognostic scenarios are shown in Figure 2b. In comparison to a baseline sce-
nario of no prognostic tool (modelled as a prognostic with a sensitivity and 
specificity of 50%), IMCI is predicted to have a small incremental impact on 
mortality. This is largely driven by the fact that the sensitivity of IMCI in identi-
fying severe cases is only 50–60%, and hence not much greater than ‘chance’. 
By contrast, we predict that distribution of pulse oximetry to affected commu-
nities could result in much greater reductions in mortality. This is driven by both 
the higher sensitivity of pulse oximetry (65–75% for PO1, 80–90% for PO2) 
compared with IMCI (50–60%) and our assumption that there would be a 
higher adherence rate to PO1 and PO2 (80–90% for severe cases) compared 
with IMCI (60–70% for severe cases). The countries with the poorest rates of 
community-based treatment have the greatest reduction in mortality when only 
IMCI is considered (compared with no prognostic tool); whereas for PO1 and 
PO2, the countries with the highest incidence of disease are predicted to have 
the greatest reduction in mortality compared with no prognostic tool used.
The reduction in mortality under IMCI, PO1 and PO2 compared with 
the absence of a prognostic tool can be translated directly into estimates of 
deaths averted per 1,000 children at risk. Our estimates of the number of 
deaths averted by PO1 and PO2 is substantially higher than those estimated 
to be averted by IMCI, with the highest impact per 1,000 children in Soma-
lia, Mali and Niger (Fig. 3a). Although the effect of IMCI on deaths averted 
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Figure 2 | Pneumonia incidence and mortality. a, Estimated under-5 pneumonia 
incidence predicted by the model and previously reported mortality12 in top 15 
countries with the highest burden. b, Median estimates of pneumonia deaths 
per 1,000 children under 5 across the 15 countries with the highest mortality for 
four different community-level prognostics — none, integrated management of 
childhood illness (IMCI), combined IMCI and pulse oximetry with 70% sensitivity 
(PO1) and combined IMCI and pulse oximetry with 85% sensitivity (PO2). DRC, 
Democratic Republic of the Congo.
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is small relative to pulse oximetry, there is still a benefit compared with the 
absence of a prognostic tool. The estimated impact of pulse oximetry is 
more apparent when translated to absolute values scaled to country-specif-
ic under-5 population sizes (Fig. 3b). In absolute terms, the introduction of 
pulse-oximetry devices is estimated to result in the greatest annual reduc-
tions in pneumonia deaths in India (75,500 deaths averted per year for PO2) 
and in Nigeria (15,400 deaths averted per year for PO2) owing to their large 
under-five populations (128 million and 27 million, respectively). Collectively, 
we estimate that the implementation of PO1 (the more conservative estimate 
of IMCI and pulse-oximetry sensitivity) could avert 103,000 (90% range = 
77,000–135,000) deaths annually across the 15 countries with the highest 
burden. For PO2, this increases to 148,000 (90% range = 112,000–193,000).
A key aim of improved prognostic tools is to increase the number of pa-
tients with severe disease receiving correct hospital referral. Using Nigeria as a 
country-level example, we estimated that the proportion of people with severe 
cases receiving hospital referral could increase by 44% by implementing PO1 
or 62% by implementing PO2. We also estimated a substantial reduction in 
incorrect treatment — with the number of people with severe disease receiv-
ing community-based care alone (under treatment) decreasing by 19% (PO1) 
and 25% (PO2). However, a  small increase in number of people with non-se-
vere cases who receive hospital referral (over-treatment) was also predicted 
(from 3.99% of cases to 5.08% for both PO1 and PO2); this is due to the 
assumption that higher adherence is associated with a severe prognosis made 
by PO1 or PO2 compared with IMCI alone.
Increasing the sensitivity of the prognostic tool — which is assumed from 
adding pulse oximeters to existing IMCI — only has a substantial effect if oth-
er aspects of the health system are functioning at reasonable levels. Using 
Nigeria as a country-level example, we identified four key variables that deter-
mined the additional impact of a pulse oximeter — the availability of amoxicil-
lin, hospital care, oxygen within the hospital and the prognostic tool. 
The reduction in mortality is slightly more sensitive to the availability of 
community-based care than the availability of hospital-based care (Fig. 4a). 
This is due to two assumptions: if a person is referred to hospital, but is unable 
to access hospital care, then community-based care may instead be accessed; 
and community-based care includes the provision of a full course of amoxicil-
lin. Therefore, if hospital-based care is unavailable, cases will probably receive 
amoxicillin instead, and a proportion of these will be cured by amoxicillin. 
Providing a more sensitive prognostic tool only had a substantial impact on 
mortality when the availability of hospital care was greater than 20%, when 
the oxygen availability exceeded 60% and when the prognostic tool was 
available in more than 60% of communities (Fig. 4a). We further investigated 
the impact of reduced oxygen availability on both deaths averted and cost-ef-
fectiveness (Fig. 4b) and found that oxygen availability (parameterized as the 
hospital cure rate) needs to be at least 60% for deaths to be averted by PO2 
compared with IMCI alone. For cost-effectiveness to be less than US$40 per 
DALY averted, oxygen availability should exceed 70% (Fig. 4b). 
PO1 and PO2 are assumed to have both higher sensitivity and higher ad-
herence to severe prognosis than IMCI alone. To assess the relative contribu-
tions of these two parameters, the change in incidence of cases in each of the 
four treatment states compared with IMCI was calculated for five scenarios: 
with the increase in adherence to a severe prognosis only; the increase in sensi-
tivity for PO1 only; the PO1 combination of increased adherence and sensitivity; 
the increase in sensitivity for PO2 only; and the PO2 combination of increased 
adherence and sensitivity (Supplementary Fig. 3). We found that increasing 
each parameter alone had a substantial effect on the incidence of deaths and 
treated cases. Increased adherence to a severe prognosis alone caused more 
non-severe cases to be incorrectly treated owing to the poor sensitivity of IMCI 
that caused some non-severe cases to be given a prognosis of severe — these 
are then treated because of the higher adherence. The increase in severe prog-
nosis adherence resulted in a small increase in incorrect treatment for non-se-
vere cases (relative to the total number of non-severe cases), but a substantial 
increase in correct treatment for severe cases (relative to the total number of 
severe cases). The combination of increased adherence and prognostic sensi-
tivity had the largest impact on the correct treatment of severe cases. 
Across all the countries studied, community-based care costs (US$0.56–
3.70 per course of amoxicillin15) are small in comparison to the corresponding 
hospital costs ($6.44–130.34 for a 7-day inpatient stay15). The estimated cost of 
the intervention itself (approximately $165 per 1,000 children per year) is also 
estimated to be lower than the additional health-care costs in most of the coun-
tries. As such, overall increases in health-care costs under pulse oximetry are 
largely associated with higher hospital referral rates for severe pneumonia cases.
The cost-effectiveness of implementing pulse oximetry in the 15 countries 
with the highest burden is shown in Figure 5. PO1 and PO2 are most cost-ef-
fective in Niger ($3.72 and $2.97 per DALY, respectively), the Democratic 
Republic of the Congo ($6.81 and $4.81 per DALY, respectively) and Ethiopia 
($6.57 and $5.00 per DALY, respectively), partly driven by the comparatively 
lower costs of hospital care in those countries. For comparison, an insecti-
cide-treated mosquito net (ITN) to prevent malaria is estimated to cost be-
tween $5 and $31 per DALY averted19, whereas HIV antiretroviral therapy has 
been estimated to cost upwards of $150 per DALY averted20. 
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Figure 3 | Deaths averted by prognostic tools across 15 countries. a, Estimated deaths averted per 1,000 children per year under integrated management of 
childhood illness (IMCI), PO1 (combined IMCI and pulse oximetry with 70% sensitivity) and PO2 (combined IMCI and pulse oximetry with 85% sensitivity) each 
compared with a baseline of no prognostic. b, Estimated absolute number of deaths averted by PO1 and PO2 compared with IMCI alone. Error bars show 90% range 
from the sensitivity analysis. DRC, Democratic Republic of the Congo. 
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DISCUSSION
Using a simple model that links care pathways to the progression of pneumonia 
in young children, we predict that a combination of pulse oximetry with current 
IMCI guidelines has the potential to avert up to 148,000 deaths per year in 
the 15 countries with the highest burden of pneumonia across Africa and Asia, 
under the assumption that there is more than 90% prognostic tool and sup-
plementary oxygen availability. This equates to about one-sixth of all deaths 
owing to community-acquired pneumonia in the developing world. For com-
parison, it has been estimated that complete elimination of low birth weight 
would prevent 25% of pneumonia deaths in developing countries, with a sim-
ilar proportion prevented by eliminating malnutrition21. Analysis of the impact 
of the pneumococcal vaccine for infants, PCV10, predicted that the vaccine has 
the potential to directly avert around 262,000 deaths in under-5s across 72 
countries22. The relative ease of implementation of a pulse oximetry-based in-
tervention (even with the assumption of perfect availability) compared with the 
elimination of low birth weight or malnutrition makes it an important candidate 
for an intervention against pneumonia in resource-poor settings.
On top of the large reduction in deaths, we predict that the addition of pulse 
oximetry to IMCI has the potential to increase the correct treatment of severe cas-
es by an estimated 44%. When modelling the effect of PO1 and PO2 compared 
with IMCI, we increased two key parameters to simulate the implementation of 
pulse oximetry. These were prognostic sensitivity (which was set to be higher for 
PO1 and PO2 than for IMCI) and adherence to a severe prognostic result (also 
higher for PO1 and PO2 than for IMCI). Both substantially contribute to an in-
crease in the correct treatment of severe cases and thus the predicted reduction 
in pneumonia deaths. Sensitivity analysis showed that an increase in either of 
these characteristics alone has the potential to prevent deaths. These substantial 
burden reductions are explained by the relatively low sensitivity of IMCI for de-
tecting severe cases (just 55% compared with a potential 70–85% for pulse ox-
imetry combined with IMCI), and the very high burden of pneumonia in these 15 
countries (910,000 deaths attributed to pneumonia in under-5s in 2010 (ref. 12).
The incremental cost-effectiveness of PO1 and PO2 over IMCI was found 
to be very low in 14 of the 15 countries (less than $30 per DALY averted). For 
reference, the gross domestic product (GDP) per capita across these 14 coun-
tries ranged from $400 to $3,000 in 2013. Compared with the cost-effective-
ness of the distribution of PCV10, estimated to be $100 per DALY averted22, 
this seems to be remarkably favourable. However, the extra costs of providing 
oxygen support were not taken into account in the calculations of cost-effec-
tiveness, owing to a lack of data on the availability of oxygen support at the 
country level. Including the costs in the analyses will decrease the cost-effec-
tiveness. Nevertheless, we predict that when coupled with the additional costs 
of oxygen support, pulse oximetry will still compare favourably with the PCV10 
vaccine. For example, a study in Papua New Guinea estimated the cost-effec-
tiveness of improving oxygen support in this area (including oxygen concentra-
tors and the provision of pulse oximeters) to be $50 per DALY averted23. 
There were several limitations to our analysis. One of these was the lack 
of country-specific data to inform our parameter for access to hospital care. 
We assumed that 61% of people who were referred to hospital would access 
hospital care, based on data from a retrospective case review study of chil-
dren with severe pneumonia in Tanzania24. More realistically, we know that the 
proportion of children reaching an appropriate health facility may vary signifi-
cantly between countries and so having one single parameter for all countries 
could result in inaccurate estimates. However, our sensitivity analysis showed 
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Figure 4 | Sensitivity analyses. a, The relationship between prognostic scenario 
parameters, prognostic sensitivity and the estimated annual pneumonia deaths 
per 1,000 children under 5 under varying prognostic scenarios: 1) the availability 
of amoxicillin (community-based care); 2) the availability of hospital care; 3) the 
availability of the prognostic tool; and 4) the availability of oxygen (hospital care). 
All other parameters were fixed at their central values. b, The impact of oxygen 
availability on cost-effectiveness and deaths averted, assuming a combined 
integrated management of childhood illness and pulse oximetry sensitivity of 
85% (PO2). All scenarios are modelled using country-specific parameters for 
Nigeria. DALY, disability-adjusted life year.
Figure 5 | Cost-effectiveness of prognostic tools. Estimated cost-effectiveness 
(US$ per disability adjusted life year (DALY)) of PO1 (combined integrated 
management of childhood illness (IMCI) and pulse oximetry with 70% sensitivity) 
and PO2 (combined IMCI and pulse oximetry with 85% sensitivity) compared 
with IMCI in the 15 countries with the highest burden of pneumonia. The 
numbers indicate the median estimate whereas bars represent the 90% range. 
DRC, Democratic Republic of the Congo.
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that the model is less sensitive to hospital access than community-based care 
access. Another limitation was a lack of data on the availability of oxygen sup-
port across the 15 countries and how it is distributed throughout the health 
system. Linked to this was our assumption that the hospital systems in each 
country were substantial enough to support the extra cases that would be hos-
pitalized. More field data on the hospital systems in each country is required 
to inform and expand the model to appropriately address these limitations. 
Nevertheless, it is clear that for any new prognostic to have impact there is the 
need to also invest in strengthening the existing primary and tertiary health-
care facilities so that appropriate care is provided to those that are referred. 
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